Acetylcysteine injection - Cumberland Pharmaceuticals
Alternative Names: N-acetylcysteine (NAC) injection - Cumberland Pharmaceuticals; Acetadote; Intravenous NAC - Cumberland PharmaceuticalsLatest Information Update: 02 Oct 2021
At a glance
- Originator Cumberland Pharmaceuticals
- Developer Al-Nabil; Cumberland Pharmaceuticals; GerminMED; Harbin Gloria Pharmaceuticals
- Class Anti-inflammatories; Antibronchitics; Antidotes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
- Mechanism of Action Antioxidants; Free radical inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Poisoning
- Phase II Kidney disorders
- Discontinued Liver failure
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for clinical-Phase-Unknown development in Poisoning in China (IV, Injection)
- 15 May 2019 Acetylcysteine injection licensed to Winhealth Pharma in China, Hong Kong and Macau
- 04 Jan 2018 Phase II development is ongoing in Kidney disorders (Prevention) in USA